Study to Evaluate MET642 in Patients With NASH

• Status: Active, not recruiting
• Trial end date: 2022-02-14
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Metacrine, Inc.

Criteria

Inclusion Criteria:

• Diagnosis of NASH via biopsy, magnetic resonance elastography (MRE), or transient elastography (TE, FibroScan)

• Liver fat content ≥ 10% as measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF).

Exclusion Criteria:

• History of significant liver disease (eg, alcoholic liver disease, viral hepatitis, etc.) or liver transplant.

• Presence of cirrhosis on any prior liver biopsy (stage 4 fibrosis).

• Excessive consumption of alcohol.